Related Experiment Video
Updated: May 7, 2026
Advanced Diffusion Imaging in The Hippocampus of Rats with Mild Traumatic Brain Injury
Published on: August 14, 2019
Metabolic pathway dysregulation in diffuse axonal injury: a multimodal biomarker approach for early diagnosis and
Weiliang Chen1, Shengwen Li2, Taotao Zhang3
1Department of Neurosurgery, Haining People's Hospital, Zhejiang, China.
Background:
Diffuse axonal injury (DAI), a severe subtype of traumatic brain injury (TBI), lacks reliable early diagnostic biomarkers, contributing to poor clinical outcomes. Systemic metabolic pathway dysregulation in DAI remains poorly characterized, limiting targeted therapeutic strategies.
Objectives:
Identify DAI-specific metabolic network disruptions and evaluate their diagnostic and prognostic utility.
Methods:
In this prospective cohort study, serum metabolomics profiling, pathway enrichment analysis, and machine learning were integrated with clinical assessments in 64 adults with acute TBI (30 DAI, 34 non-DAI). Untargeted metabolomics via UPLC-LTQ-Orbitrap MS identified differential metabolites, which were mapped to biological pathways using MetaboAnalyst 5.0. Diagnostic and prognostic performance of pathway-based models was assessed using ROC analysis.
Results:
DAI patients exhibited distinct metabolic perturbations, with significant dysregulation in mitochondrial fatty acid oxidation (FAO) and phospholipid metabolism. Key discriminative metabolites included carnitine C8:1 (VIP = 3.26) and lysophosphatidylcholine 22:3 sn-2, which correlated with Marshall CT scores (ρ = 0.62, p < 0.001) and pupillary reflex loss. A multi-parameter model integrating FAO and phospholipid degradation markers achieved superior diagnostic accuracy (AUC = 0.927, 95% CI: 0.86-0.98) compared to clinical models (AUC = 0.744). Pathway disruptions further predicted 3-month functional outcomes (GOSE AUC = 0.912).
Conclusion:
DAI involves systemic metabolic network dysfunction centered on mitochondrial energetics and lipid metabolism. Pathway-centric biomarkers enhance diagnostic precision and prognostication, offering a novel framework for biomarker-driven management of TBI. These findings highlight mitochondrial FAO and phospholipid homeostasis as potential therapeutic targets, addressing a critical gap in DAI care.
Insights
Diffuse axonal injury (DAI), a severe traumatic brain injury (TBI), shows metabolic network dysfunction. New biomarkers from fatty acid oxidation and phospholipid metabolism improve diagnosis and prognosis for TBI patients.
Area of Science:
- Neuroscience
- Metabolomics
- Biomarker Discovery
Background:
- Diffuse axonal injury (DAI) is a severe traumatic brain injury (TBI) subtype with limited early diagnostic biomarkers, leading to poor outcomes.
- Systemic metabolic pathway dysregulation in DAI is not well understood, hindering targeted therapies.
Purpose of the Study:
- To identify DAI-specific metabolic network disruptions.
- To evaluate the diagnostic and prognostic utility of these metabolic disruptions.
Main Methods:
- Prospective cohort study of 64 acute TBI patients (30 DAI, 34 non-DAI).
- Serum metabolomics profiling using UPLC-LTQ-Orbitrap MS.
- Pathway enrichment analysis and machine learning for diagnostic and prognostic modeling.
Main Results:
- DAI patients showed distinct metabolic perturbations, particularly in mitochondrial fatty acid oxidation (FAO) and phospholipid metabolism.
- Key metabolites like carnitine C8:1 and lysophosphatidylcholine 22:3 sn-2 correlated with injury severity and neurological signs.
- A multi-parameter model integrating FAO and phospholipid markers achieved high diagnostic accuracy (AUC=0.927) and predicted functional outcomes.
Conclusions:
- DAI involves systemic metabolic dysfunction in mitochondrial energetics and lipid metabolism.
- Pathway-centric biomarkers significantly improve TBI diagnosis and prognostication.
- Mitochondrial FAO and phospholipid homeostasis are potential therapeutic targets for DAI.
